Moving Toward Total Therapy in AML: Personalized Treatments Improve Post-Transplant Outcome
Mené sur 356 patients atteints d'une leucémie myéloïde aiguë présentant une duplication interne en tandem au niveau du gène FLT3, cet essai randomisé évalue l'efficacité, du point de vue de la survie sans récidive, et la toxicité du giltéritinib en traitement d'entretien après une greffe allogénique de cellules souches hématopoïétiques
Survival in fit adults with AML has steadily improved over the past decade; thanks, largely, to the advent of new drugs targeting molecular pathways pivotal to disease pathogenesis.1,2 Despite this notable progress, allogeneic stem cell transplantation (allo-SCT), a technique pioneered more than half a century ago, still remains the most potent antileukemic modality in high-risk AML, and advances in transplant technology now allow the delivery of a potentially curative graft-versus-leukemia (GVL) effect to increasing numbers of fit adults whose outcome with conventional chemotherapy alone is predicted to be poor. By contrast, however, to the increasingly personalized pharmacological landscape of adult AML treatment, allo-SCT remains a blunt, if highly effective, therapeutic modality which has thus far failed to take advantage of the opportunities presented by targeted therapies to improve transplant outcome.